In addition, one study utilizing sera collected from CLL patients demonstrated patients were more frequently deficient in C1q, C3, and C4 complement proteins and that their sera was more readily exhausted of complement activity following anti-CD20 mAb treatment, resulting in lowered CDC activity (119). This evidence concerns the gene C3 and B-cell chronic lymphocytic leukemia.